Cardiovascular Diabetology · 2024 · 32 citations · 49 references
Life SciencesBiochemistryCardiologyDiabetologyMitochondrial BiologyMolecular PhysiologyCardiac PhysiologyCardiovascular DiseaseEndothelial DysfunctionMitochondrial DynamicsMitochondrial DysfunctionMitochondrial PhysiologyCardiac Mitochondrial FunctionDiabetic CardiomyopathyGlutathione Peroxidase 4Mitochondrial Dynamics RegulationMitogen-activated Protein Kinase KinaseMitogen-activated Protein Kinase SignalingProtein S-nitrosylationVascular Endothelial Dysfunction
Dynamin-related protein 1 (Drp1) is a crucial regulator of mitochondrial dynamics, the overactivation of which can lead to cardiovascular disease. Multiple distinct posttranscriptional modifications of Drp1 have been reported, among which S-nitrosylation was recently introduced. However, the detailed regulatory mechanism of S-nitrosylation of Drp1 (SNO-Drp1) in cardiac microvascular dysfunction in diabetes remains elusive. The present study revealed that mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) was consistently upregulated in diabetic cardiomyopathy (DCM) and promoted SNO-Drp1 in cardiac microvascular endothelial cells (CMECs), which in turn led to mitochondrial dysfunction and cardiac microvascular disorder. Further studies confirmed that MAP4K4 promoted SNO-Drp1 at human C644 (mouse C650) by inhibiting glutathione peroxidase 4 (GPX4) expression, through which MAP4K4 stimulated endothelial ferroptosis in diabetes. In contrast, inhibition of MAP4K4 via DMX-5804 significantly reduced endothelial ferroptosis, alleviated cardiac microvascular dysfunction and improved cardiac dysfunction in db/db mice by reducing SNO-Drp1. In parallel, the C650A mutation in mice abolished SNO-Drp1 and the role of Drp1 in promoting cardiac microvascular disorder and cardiac dysfunction. In conclusion, our findings demonstrate that MAP4K4 plays an important role in endothelial dysfunction in DCM and reveal that SNO-Drp1 and ferroptosis activation may act as downstream targets, representing potential therapeutic targets for DCM.
49
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Kirill Bersuker, Joseph M. Hendricks, Zhipeng Li et al. · Nature · 2019 · 3.6K citations · Full text
S-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury
Dong‐Hyung Cho, Tomohiro Nakamura, Jianguo Fang et al. · Science · 2009 · 1.1K citations · Full text
Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus
Sherene M. Shenouda, Michael E. Widlansky, Kai Chen et al. · Circulation · 2011 · 568 citations · Full text